antibody-drug conjugates

11 · 20 / page

Ask MedXY AI

Latest news

Tag

newsantibody-drug conjugatesgynecologic cancers

Real-World Antibody-Drug Conjugate Outcomes in Gynecologic Cancers Appear Consistent Across Demographic Subgroups

By MedXY|May 4, 2026

In a single-center real-world cohort, survival with mirvetuximab soravtansine, trastuzumab deruxtecan, and tisotumab vedotin broadly mirrored pivotal trials, with no independent survival differences by age, race, or ethnicity after adjustme

Targeting the Sugar Coat: Oncofetal Chondroitin Sulfate Emerges as a Precision ADC Target in AML

Hematology-Oncologyacute myeloid leukemiaantibody-drug conjugates

antibody-drug conjugates

Latest news

Real-World Antibody-Drug Conjugate Outcomes in Gynecologic Cancers Appear Consistent Across Demographic Subgroups

Targeting the Sugar Coat: Oncofetal Chondroitin Sulfate Emerges as a Precision ADC Target in AML

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

Targeted HEV Modulation: A Novel Antibody-Drug Conjugate Strategy to Overcome Cardiac Allograft Rejection

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC: Efficacy, Safety, and the Challenges of Combination Therapy in DESTINY-Lung03

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies